Company profile
Amphastar Pharmaceuticals, Inc.
Pipeline8 assets
- Insulin AspartAMP-004 / interchangeable biosimilar insulin / Diabetes
- Recombinant Human InsulinAMP-005 / interchangeable biosimilar insulin / Diabetes
- AMP-028AMP-028 / biosimilar
- Intranasal epinephrineAMP-019 / adrenergic receptors / intranasal small molecule / Allergy/ImmunologyAnaphylaxis/allergic reactionsdevelopment
- AMP-105AMP-105 / peptide / OncologyPoorly treated cancersdevelopmentUnited StatesCanada
- AMP-107AMP-107 / VEGFR / topical eye-drop peptide / OphthalmologyWet age-related macular degenerationdevelopmentUnited StatesCanada
- AMP-109AMP-109 / peptide-docetaxel conjugate / OncologyCancerdevelopmentUnited StatesCanada
- AMP-110AMP-110 / ACTH receptor pathway / synthetic human corticotropin analog peptideMultiple indicationsdevelopmentUnited StatesCanada
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.